Showing results (1161-1170 of 1,797) with videos related to
Sort By:
Pageof 180
Mabs|February 25, 2016
The application of mathematical modelling to the design of bispecific monoclonal antibodiesTamara J van Steeg, Kirsten Riber Bergmann, Nazzareno Dimasi, et al.Mabs|March 11, 2016
Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLLDe-Kuan Chang, Vinodh B Kurella, Subhabrata Biswas, et al.Mabs|March 11, 2016
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidityAndrew D Tustian, Christine Endicott, Benjamin Adams, et al.Mabs|December 18, 2014
Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014James W Larrick, Paul W H I Parren, James S Huston, et al.Mabs|December 18, 2014
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancerSaskia Meyer, Jeanette H W Leusen, Peter BorossMabs|December 18, 2014
Physicochemical characterization of RemsimaSoon Kwan Jung, Kyoung Hoon Lee, Jae Won Jeon, et al.Mabs|December 18, 2014
Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programsAlex Colbert, Amber Umble-Romero, Samantha Prokop, et al.Mabs|December 18, 2014
Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibodyNoriyuki Kasai, Yukitaka Yoshikawa, Junichi EnokizonoMabs|December 18, 2014
A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodiesJan Stracke, Thomas Emrich, Petra Rueger, et al.Mabs|December 18, 2014
Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodiesMagdalena Winiarska, Kamil Bojarczuk, Beata Pyrzynska, et al.Pageof 180